Mnemo Therapeutics Announces Publication in Cancer Discovery on Ablation of SUV39H1 for Long-Term Protection Against Solid Tumors.

Mnemo Therapeutics, a biotechnology company, has published a preclinical study in Cancer Discovery that demonstrates the potential of inactivating the enzyme SUV39H1 to enhance the differentiation and persistence of CAR T cells. The study shows that genetic ablation of SUV39H1 reprograms T cells to express memory-associated genes and reduce exhaustion-associated genes, leading to improved efficacy and protection against tumor relapse in mouse models of lung cancer and other solid tumors. The findings suggest that inactivating SUV39H1 could be a promising approach to improving the long-term success of immunotherapy treatments for tumors. [Extracted from the article]